Physician profile
Robert Butcher
NPI 1396735767
$6,564.35
in general payments reported to CMS, 2019-2025
46 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $566 · 2021: $954 · 2022: $869 · 2023: $1,191 · 2024: $1,085 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,428 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,427.72 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,041.97 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $645.74 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $642.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $573.85 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $475.10 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $392.14 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.64 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $290.58 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company Ltd. | $183.37 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $126.92 | 2021-2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $125.36 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.07 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $119.05 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.11 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $109.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $105.00 | 2019-2023 | Veozah |
| Allergan, INC. | $88.68 | 2019-2020 | |
| Amarin Pharma, INC. | $79.40 | 2019-2021 | |
| Clarus Therapeutics INC. | $72.61 | 2021 | |
| Antares Pharma, INC. | $69.88 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Kowa Pharmaceuticals America, INC. | $67.55 | 2020-2023 | Seglentis |
| Ibsa Pharma INC. | $49.21 | 2023-2024 | Tirosint, Licart, Tirosint |
| Sanofi-Aventis U.S. LLC | $48.77 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $45.08 | 2019-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $43.75 | 2019-2023 | Gardasil 9, Vaxneuvance |
| Corium, LLC | $42.74 | 2023 | Azstarys |
| Biogen, INC. | $42.01 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $41.01 | 2024-2025 | Gemtesa |
| Sanofi Pasteur INC. | $39.62 | 2019-2023 | |
| Bausch Health US, LLC | $38.94 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.61 | 2025 | Caplyta |
| Eisai INC. | $36.23 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $28.58 | 2023-2025 | Contrave |
| Lundbeck LLC | $27.80 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $27.40 | 2024 | Inspire |
| Stryker Corporation | $26.92 | 2025 | Clottriever Bold Catheter |
| Abbott Laboratories | $25.18 | 2025 | Freestyle Libre 3 |
| Harmony Biosciences LLC | $23.52 | 2025 | |
| Philips North America LLC | $22.72 | 2019 | |
| Zyla Life Sciences, INC. | $22.69 | 2019 | |
| Almatica Pharma LLC | $19.05 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.57 | 2021 | |
| Genentech USA, INC. | $16.17 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.30 | 2019 | |
| Tolmar, INC. | $13.32 | 2024 | |
| Mylan Specialty L.P. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Butcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.